Literature DB >> 21706057

Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation.

D P Mathiasen1, C Egebjerg, S H Andersen, B Rafn, P Puustinen, A Khanna, M Daugaard, E Valo, S Tuomela, T Bøttzauw, C F Nielsen, B M Willumsen, S Hautaniemi, R Lahesmaa, J Westermarck, M Jäättelä, T Kallunki.   

Abstract

Ras is one of the most frequently activated oncogenes in cancer. Two mitogen-activated protein kinases (MAPKs) are important for ras transformation: extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase 2 (JNK2). Here we present a downstream signal amplification cascade that is critical for ras transformation in murine embryonic fibroblasts. This cascade is coordinated by ERK and JNK2 MAPKs, whose Ras-mediated activation leads to the enhanced levels of three oncogenic transcription factors, namely, c-Myc, activating transcription factor 2 (ATF2) and ATF3, all of which are essential for ras transformation. Previous studies show that ERK-mediated serine 62 phosphorylation protects c-Myc from proteasomal degradation. ERK is, however, not alone sufficient to stabilize c-Myc but requires the cooperation of cancerous inhibitor of protein phosphatase 2A (CIP2A), an oncogene that counteracts protein phosphatase 2A-mediated dephosphorylation of c-Myc. Here we show that JNK2 regulates Cip2a transcription via ATF2. ATF2 and c-Myc cooperate to activate the transcription of ATF3. Remarkably, not only ectopic JNK2, but also ectopic ATF2, CIP2A, c-Myc and ATF3 are sufficient to rescue the defective ras transformation of JNK2-deficient cells. Thus, these data identify the key signal converging point of JNK2 and ERK pathways and underline the central role of CIP2A in ras transformation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21706057     DOI: 10.1038/onc.2011.230

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

Review 1.  Identification of protein interactions involved in cellular signaling.

Authors:  Jukka Westermarck; Johanna Ivaska; Garry L Corthals
Journal:  Mol Cell Proteomics       Date:  2013-03-12       Impact factor: 5.911

Review 2.  PP2A as a master regulator of the cell cycle.

Authors:  Nathan Wlodarchak; Yongna Xing
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-02-24       Impact factor: 8.250

3.  CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML.

Authors:  Claire M Lucas; Laura J Scott; Natasha Carmell; Alison K Holcroft; Robert K Hills; Alan K Burnett; Richard E Clark
Journal:  Blood Adv       Date:  2018-05-08

4.  Oncoprotein CIP2A promotes the disassembly of primary cilia and inhibits glycolytic metabolism.

Authors:  Ae Lee Jeong; Hye In Ka; Sora Han; Sunyi Lee; Eun-Woo Lee; Su Jung Soh; Hyun Jeong Joo; Buyanravjkh Sumiyasuren; Ji Young Park; Jong-Seok Lim; Jong Hoon Park; Myung Sok Lee; Young Yang
Journal:  EMBO Rep       Date:  2018-02-28       Impact factor: 8.807

5.  Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells.

Authors:  Anchit Khanna; Otto Kauko; Camilla Böckelman; Anni Laine; Ilona Schreck; Johanna I Partanen; Agnieszka Szwajda; Stefanie Bormann; Turker Bilgen; Merja Helenius; Yuba R Pokharel; John Pimanda; Mike R Russel; Caj Haglund; Kristina A Cole; Juha Klefström; Tero Aittokallio; Carsten Weiss; Ari Ristimäki; Tapio Visakorpi; Jukka Westermarck
Journal:  Cancer Res       Date:  2013-09-26       Impact factor: 12.701

6.  Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.

Authors:  Ae Lee Jeong; Sunyi Lee; Jeong Su Park; Sora Han; Chang-Young Jang; Jong-Seok Lim; Myung Sok Lee; Young Yang
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

7.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

8.  Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer.

Authors:  Zi Liu; Liang Ma; Zhe-Sheng Wen; Zheng Hu; Fu-Qun Wu; Wei Li; Jinsong Liu; Guang-Biao Zhou
Journal:  Carcinogenesis       Date:  2013-11-30       Impact factor: 4.944

9.  p90/CIP2A mediates breast cancer cell proliferation and apoptosis.

Authors:  Xinxin Liu; Bo Peng; Yang Li; Ningjing Lei; Wenjie Li; Jian-Ying Zhang
Journal:  Mol Biol Rep       Date:  2014-08-03       Impact factor: 2.316

10.  Assessment of the potential of pathological stains in human prostate cancer.

Authors:  Anchit Khanna; Rani Patil; Abhay Deshmukh
Journal:  J Clin Diagn Res       Date:  2014-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.